Drugs / OCTAAMINOACRIDINE
OCTAAMINOACRIDINE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01569516 | Jun 2011 → Jul 2012 | Alzheimer disease | Changchun Huayang High-tech Co., Ltd | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03283059 | Aug 2017 → Sep 2020 | Alzheimer disease | Shanghai Mental Health Center | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OCTAAMINOACRIDINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL263198 ↗ |
| Known as | OCTAHYDROAMINOACRIDINE SUCCINATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL263198 ↗ |
| Known as | Octohydroaminoacridine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01569516 ↗ |
| Known as | Octohydroaminoacridine succinate | “The purpose of this study is a preliminary assessment of the Octohydroaminoacridine Succinate tablets in the treatment of mild to moderate Alzheimer's disease and explore the...” NCT01569516 ↗ |
| Modality | Small molecule | — CHEMBL263198 ↗ |
| Route | Oral | “Octohydroaminoacridine Succinate Tablet:4mg P.O. tid” NCT03283059 ↗ |